SCHEMBL4293070

SCHEMBL4293070

COC(=O)c1cc2cc[n+]([O-])cc2c2cc(Cl)c(CO)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 4/20 0.36
HPGD P15428 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
NR4A2 P43354 1/20 0.35
TSHR P16473 1/20 0.35
MAPT P10636 2/20 0.34
PLA2G2A P14555 1/20 0.34
CHEK1 O14757 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CA12 O43570 1/20 0.33
CA2 P00918 1/20 0.33
CA3 P07451 1/20 0.33
CA6 P23280 1/20 0.33
CA5A P35218 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
CA5B Q9Y2D0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4292026 0.77 KDM4E (0.42) KDM4EALDH1A1HPGDNPSR1NR4A2
SCHEMBL4297736 0.71 CHEK1 (0.67) KDM4ENR4A2CHEK1
SCHEMBL522217 0.68 GAA (0.46) KDM4EALDH1A1HPGDNPSR1NR4A2
SCHEMBL28892181 0.68 MAPT (0.49) KDM4EALDH1A1HPGDNPSR1NR4A2
SCHEMBL15543978 0.67 GAA (0.43) KDM4EALDH1A1HPGDNR4A2MAPT
SCHEMBL9662171 0.66 GAA (0.47) KDM4EALDH1A1HPGDNR4A2TSHR
SCHEMBL12416208 0.65 CA12 (0.45) KDM4EALDH1A1HPGDNPSR1MAPT
SCHEMBL16735359 0.65 MAPT (0.49) KDM4EALDH1A1HPGDNPSR1NR4A2
SCHEMBL30402103 0.65 MAPT (0.49) KDM4EALDH1A1HPGDNPSR1NR4A2
SCHEMBL5025798 0.64 KDM4E (0.35) KDM4EHPGDNPSR1NR4A2PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
EP-1904449-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2008-04-02 EP disclosed
WO-2007008502-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-01-18 WO disclosed
WO-2007008502-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258852-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, CDKN1A KDM4E 366/4885ALDH1A1 2405/4885HPGD 3708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.